NASDAQ : ELVN
Enliven Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 45.08 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.30B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 35.26M | 33.80M | 23.78M | 17.66M | 7.77M | 4.29M |
| Research & Development | 89.15M | 85.86M | 80.78M | 64.57M | 31.02M | 20.47M |
| Operating Expenses | 124.41M | 119.66M | 104.55M | 82.23M | 38.79M | 24.76M |
| Operating Income | -124.41M | -119.66M | -104.55M | -82.23M | -38.79M | -24.76M |
| Interest & Investment Income | 18.49M | 16.01M | 14.89M | 11.97M | 1.13M | 22.00K |
| Other Non Operating Income (Expenses) | -8.00K | -49.00K | -2.00K | -22.00K | ||
| EBT Excluding Unusual Items | -105.93M | -103.69M | -89.67M | -70.28M | -37.66M | -24.74M |
| Merger & Restructuring Charges | -1.30M | |||||
| Other Unusual Items | 873.00K | |||||
| Pretax Income | -105.93M | -103.69M | -88.79M | -71.58M | -37.66M | -24.74M |
| Income Tax Expense | 232.00K | |||||
| Net Income | -105.93M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
| Net Income to Common | -105.93M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
| Shares Outstanding (Basic) | 63.37M | 56.66M | 47.07M | 35.55M | 3.12M | 7.81M |
| Shares Outstanding (Diluted) | 63.37M | 56.66M | 47.07M | 35.55M | 3.12M | 7.81M |
| EPS (Basic) | -1.67 | -1.83 | -1.89 | -2.01 | -12.05 | -3.17 |
| EPS (Diluted) | -1.67 | -1.83 | -1.89 | -2.01 | -12.05 | -3.17 |
| Free Cash Flow | -67.04M | -70.46M | -73.24M | -61.42M | -32.69M | -19.32M |
| Free Cash Flow Per Share | -1.06 | -1.24 | -1.56 | -1.73 | -10.46 | -2.47 |
| EBITDA | -124.28M | -119.39M | -104.24M | -81.93M | -38.58M | -24.65M |
| D&A For EBITDA | 129.00K | 263.00K | 317.00K | 297.00K | 215.00K | 115.00K |
| EBIT | -124.41M | -119.66M | -104.55M | -82.23M | -38.79M | -24.76M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 135.50M | 98.90M | 124.12M | 100.14M | 75.54M | 110.02M |
| Short-Term Investments | 759.65M | 363.73M | 189.32M | 153.01M | ||
| Cash & Short-Term Investments | 895.15M | 462.62M | 313.44M | 253.15M | 75.54M | 110.02M |
| Prepaid Expenses | 12.18M | 12.26M | 4.63M | 2.95M | 2.22M | 646.00K |
| Restricted Cash | 54.00K | 54.00K | ||||
| Other Current Assets | 10.00M | |||||
| Total Current Assets | 907.34M | 474.88M | 318.13M | 266.15M | 77.75M | 110.67M |
| Property, Plant & Equipment | 1.64M | 417.00K | 458.00K | 1.06M | 1.52M | 954.00K |
| Long-Term Deferred Charges | 217.00K | 563.00K | 3.98M | 1.65M | ||
| Other Long-Term Assets | 1.24M | 656.00K | 7.17M | 4.09M | 54.00K | 54.00K |
| Total Assets | 910.22M | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M |
| Accounts Payable | 371.00K | 2.16M | 1.34M | 532.00K | 3.44M | 2.52M |
| Accrued Expenses | 13.06M | 13.66M | 14.37M | 14.66M | 4.32M | 2.84M |
| Current Portion of Leases | 597.00K | 399.00K | 335.00K | 323.00K | 159.00K | |
| Other Current Liabilities | 133.00K | 351.00K | 204.00K | 10.36M | 1.64M | 233.00K |
| Total Current Liabilities | 14.16M | 16.57M | 15.91M | 25.89M | 9.71M | 5.75M |
| Long-Term Leases | 913.00K | 277.00K | ||||
| Other Long-Term Liabilities | 67.00K | 382.00K | 714.00K | |||
| Total Liabilities | 15.07M | 16.57M | 15.91M | 25.96M | 10.37M | 6.47M |
| Common Stock | 73.00K | 59.00K | 49.00K | 41.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 1.30B | 806.37M | 553.21M | 400.17M | 6.04M | 2.31M |
| Retained Earnings | -403.28M | -347.17M | -243.47M | -154.45M | -82.86M | -45.20M |
| Comprehensive Income & Other | -1.91M | 334.00K | 55.00K | 141.00K | ||
| Total Common Equity | 895.15M | 459.60M | 309.85M | 245.91M | -76.83M | -42.89M |
| Shareholders' Equity | 895.15M | 459.60M | 309.85M | 245.91M | 72.92M | 106.86M |
| Total Liabilities & Equity | 910.22M | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M |
| Total Debt | 1.51M | 399.00K | 335.00K | 600.00K | 159.00K | |
| Net Cash (Debt) | 893.64M | 462.22M | 313.44M | 252.81M | 74.94M | 109.86M |
| Net Cash Per Share | 14.10 | 8.16 | 6.66 | 7.11 | 23.99 | 14.06 |
| Filing Date Shares Outstanding | 73.27M | 59.80M | 49.00M | 41.35M | 12.10M | 11.64M |
| Total Common Shares Outstanding | 73.25M | 59.44M | 48.94M | 41.29M | 12.10M | 11.64M |
| Working Capital | 893.18M | 458.31M | 302.21M | 240.26M | 68.04M | 104.92M |
| Book Value Per Share | 12.22 | 7.73 | 6.33 | 5.96 | -6.35 | -3.68 |
| Tangible Book Value | 895.15M | 459.60M | 309.85M | 245.91M | -76.83M | -42.89M |
| Tangible Book Value Per Share | 12.22 | 7.73 | 6.33 | 5.96 | -6.35 | -3.68 |
| Machinery | 390.00K | 263.00K | 1.38M | 1.41M | 1.26M | 652.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -105.93M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
| Depreciation & Amortization | 129.00K | 263.00K | 317.00K | 297.00K | 215.00K | 115.00K |
| Other Amortization | 1.74M | |||||
| Loss (Gain) From Sale of Assets | 106.00K | 106.00K | 11.00K | |||
| Loss (Gain) From Sale of Investments | 522.00K | -227.00K | 424.00K | -4.60M | ||
| Stock-Based Compensation | 40.81M | 34.02M | 20.17M | 12.91M | 3.19M | 1.92M |
| Other Operating Activities | 400.00K | 353.00K | -553.00K | 306.00K | ||
| Change in Accounts Payable | -2.21M | 817.00K | 810.00K | -2.25M | 411.00K | 1.73M |
| Change in Other Net Operating Assets | -764.00K | -1.94M | -5.35M | 3.65M | 27.00K | 1.83M |
| Operating Cash Flow | -66.94M | -70.30M | -73.19M | -61.27M | -32.08M | -19.13M |
| Capital Expenditures | -98.00K | -158.00K | -44.00K | -149.00K | -612.00K | -191.00K |
| Sale of Property, Plant & Equipment | 213.00K | 213.00K | ||||
| Investment in Securities | -390.83M | -173.90M | -36.83M | -148.26M | ||
| Other Investing Activities | 873.00K | |||||
| Investing Cash Flow | -390.72M | -173.84M | -36.00M | -148.41M | -612.00K | -191.00K |
| Issuance of Common Stock | 473.94M | 219.08M | 133.16M | 243.59M | 591.00K | 690.00K |
| Other Financing Activities | -217.00K | -217.00K | -9.30M | -2.39M | -1.71M | |
| Financing Cash Flow | 473.73M | 218.87M | 133.16M | 234.29M | -1.80M | -1.02M |
| Net Cash Flow | 16.07M | -25.27M | 23.98M | 24.61M | -34.49M | -20.34M |
| Free Cash Flow | -67.04M | -70.46M | -73.24M | -61.42M | -32.69M | -19.32M |
| Free Cash Flow Per Share | -1.06 | -1.24 | -1.56 | -1.73 | -10.46 | -2.47 |
| Levered Free Cash Flow | -45.26M | -47.98M | -46.23M | -32.95M | -17.48M | -9.83M |
| Unlevered Free Cash Flow | -45.26M | -47.98M | -46.23M | -32.95M | -17.48M | -9.83M |
| Cash Income Tax Paid | 232.00K | |||||
| Change in Working Capital | -2.98M | -1.12M | -4.54M | 1.40M | 438.00K | 3.57M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.24B | 913.95M | 1.10B | 570.37M | ||
| Enterprise Value | 2.35B | 436.87M | 807.58M | 307.23M | ||
| Last Close Price | 44.25 | 15.40 | 22.50 | 13.84 | ||
| PB Ratio | 3.62 | 1.99 | 3.55 | 2.32 | ||
| P/TBV Ratio | 3.62 | 1.99 | 3.55 | 2.32 | ||
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | |
| Net Debt / Equity Ratio | -1.00 | -1.01 | -1.01 | -1.03 | -1.03 | -1.03 |
| Net Debt / EBITDA Ratio | 7.19 | 3.87 | 3.01 | 3.09 | 1.94 | 4.46 |
| Net Debt / FCF Ratio | 13.33 | 6.56 | 4.28 | 4.12 | 2.29 | 5.68 |
| Quick Ratio | 63.21 | 27.92 | 19.70 | 9.78 | 7.78 | 19.12 |
| Current Ratio | 64.07 | 28.66 | 19.99 | 10.28 | 8.00 | 19.24 |
| Return on Equity (ROE) | -15.31% | -26.95% | -32.04% | -44.90% | -41.90% | -20.94% |
| Return on Assets (ROA) | -11.00% | -18.65% | -21.87% | -28.94% | -24.66% | -12.67% |
| Return on Capital Employed (ROCE) | -13.90% | -26.00% | -33.70% | -33.40% | -52.70% | -23.00% |
| Earnings Yield | -3.78% | -11.35% | -8.10% | -12.55% | ||
| FCF Yield | -2.07% | -7.71% | -6.66% | -10.77% | ||
| Buyback Yield / Dilution | -26.53% | -20.38% | -32.43% | -1,037.74% | 60.02% | -56.70% |